Compare CXM & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | TNDM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2021 | 2013 |
| Metric | CXM | TNDM |
|---|---|---|
| Price | $5.30 | $15.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 19 |
| Target Price | $8.28 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $857,200,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $2.52 | $8.11 |
| Revenue Next Year | $4.94 | $11.85 |
| P/E Ratio | $108.60 | ★ N/A |
| Revenue Growth | 7.64 | ★ 7.93 |
| 52 Week Low | $4.72 | $11.46 |
| 52 Week High | $8.28 | $29.65 |
| Indicator | CXM | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 35.01 |
| Support Level | $5.18 | $14.44 |
| Resistance Level | $5.60 | $16.50 |
| Average True Range (ATR) | 0.21 | 1.04 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 26.32 | 13.14 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.